EXT1 and EXT2 Variants in 22 Chinese Families With Multiple Osteochondromas: Seven New Variants and Potentiation of Preimplantation Genetic Testing and Prenatal Diagnosis

Ye Wang1†, Liangying Zhong2†, Yan Xu3,4, Lei Ding5, Yuanjun Ji1, Sacha Schutz6,7, Claude Férec6,7, David N. Cooper8, Caixia Xu9*, Jian-Min Chen6* and Yanmin Luo1*

1 Fetal Medicine Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2 Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 3 Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 4 Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou, China, 5 Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 6 Inserm, Univ Brest, EFS, UMR 1078, GGB, Brest, France, 7 CHRU Brest, Brest, France, 8 School of Medicine, Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom, 9 Research Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Multiple osteochondromas (MO), the most common type of benign bone tumor, is an autosomal dominant skeletal disorder characterized by multiple cartilage-capped bony protruberances. In most cases, EXT1 and EXT2, which encode glycosyltransferases involved in the biosynthesis of heparan sulfate, are the genes responsible. Here we describe the clinical, phenotypic and genetic characterization of MO in 22 unrelated Chinese families involving a total of 60 patients. Variant detection was performed by means of a battery of different techniques including Sanger sequencing and whole-exome sequencing (WES). The pathogenicity of the missense and splicing variants was explored by means of in silico prediction algorithms. Sixteen unique pathogenic variants, including 10 in the EXT1 gene and 6 in the EXT2 gene, were identified in 18 (82%) of the 22 families. Fourteen (88%) of the 16 variants were predicted to give rise to truncated proteins whereas the remaining two were missense. Seven variants were newly described here, further expanding the spectrum of MO-causing variants in the EXT1 and EXT2 genes. More importantly, the identification of causative variants allowed us to provide genetic counseling to 8 MO patients in terms either of preimplantation genetic testing (PGT) or prenatal diagnosis, thereby preventing the reoccurrence of MO in the corresponding families. This study is the first to report the successful implementation of PGT in MO families and describes the largest number of subjects undergoing prenatal diagnosis to date.

Keywords: EXT1 gene, EXT2 gene, multiple osteochondromas, pathogenic variant, preimplantation genetic testing, prenatal diagnosis
INTRODUCTION

Multiple osteochondromas (MO) (OMIM 133700-133701), also known as hereditary multiple exostoses (HME) or osteocartilaginous exostosis, is an autosomal dominant skeletal disorder characterized by the formation of benign cartilage-capped bony protuberances, typically arising on the metaphyses of long tubular bones (Bovee, 2008). The malformation of legs, forearms and hands is a frequent manifestation (Matsubara et al., 2006). The prevalence of MO is estimated to be 1/50,000 (Wicklund et al., 1995) and would appear to be higher in males (male-to-female ratio, 1.5:1) (D’Arienzo et al., 2019), making it one of the most frequent causes of skeletal dysplasia. MO is characterized by significant inter- and intra-familial phenotypic heterogeneity, including variation in the number and size of osteochondromas, the number and location of the bones involved, and the degree of the deformities arising (Peterson, 1989). Osteochondromas are rarely present at birth, but rather appear and grow during the first decade of life, finally ceasing to grow when the growth plates close at the end of puberty. Approximately 62% of MO patients have a positive family history, with nearly complete penetrance (Schmiele et al., 1994).

Benign as the osteochondromas are, they can lead to several complications. By exerting pressure on neighboring tissues, osteochondromas cause pain, nerve compression, and other conditions (Pedrini et al., 2005). Skeletal malformations are also observed in MO patients with limb length inequalities, restricted range of joint motion and short stature (Porter et al., 2004). At present there is no etiological treatment, so surgery may be the only way to correct the severe deformities. Although MO does not in itself affect life expectancy, malignant transformation to a chondrosarcoma occurs in 1–5% of cases (Peterson, 1989; Pedrini et al., 2011).

MO is genetically heterogeneous. To date, three loci for MO have been mapped and two genes, EXT1 (Entrez gene ID: 2131, alias: Exostosin1) and EXT2 (Entrez gene ID: 2132, alias: Exostosin2), have been cloned (Ahn et al., 1995; Stickens et al., 1996). EXT1 consists of 11 exons and spans ~312 kb at 8q24 (Ludecke et al., 1997), while EXT2 comprises 16 exons and is located at 11p11.2, spanning ~150 kb (Clines et al., 1997). The genes belong to the EXT multigene family, are ubiquitously expressed and act as tumor suppressors. All members of this family encode proteins that are involved in the adhesion and/or polymerization of heparin sulfate (HS) chains at HS proteoglycans (HSPG’s) (Lind et al., 1998; McCormick et al., 1998; Busse et al., 2007). EXT1 and EXT2 function as glycosyltransferases that participate in the biosynthesis of heparin sulfate (HS) to modify proteoglycans. HS proteoglycans, synthesized by chondrocytes and secreted to the extracellular matrix of the growth plate, play critical roles in growth plate signaling and remodeling.

To date, hundreds of EXT1 and EXT2 variants have been registered in the Human Gene Mutation Database (HGMD) (Stenson et al., 2020) as well as in the EXT1 and EXT2 locus-specific mutation databases. Most of the known pathogenic variants cause truncation of the encoded proteins, e.g., frameshift, non-sense, and splice site mutations; pathogenic missense variants are uncommon (Santos et al., 2018; Fusco et al., 2019). The application, more recently, of structural variant-detection techniques such as multiplex ligation-dependent probe amplification (MLPA) and microarray analysis has served to increase the variant detection rate from 70 to 85% (Li et al., 2018; Fusco et al., 2019). In the present study, we report the genetic findings from 22 Chinese MO families together with the successful use of this information to potentiate preimplantation genetic testing (PGT) and prenatal diagnosis in 8 MO families.

MATERIALS AND METHODS

Ethics Statement

This study was approved by the Ethics Committee of Sun Yat-sen University. All participants (or parents/guardians when the participants were under the age of 18) gave their informed consent.

Subjects

Sixty MO patients (41 male) from 22 unrelated Chinese families participated in this study. All probands were referred to the First Affiliated Hospital of Sun Yat-sen University from January 2011 to September 2018. A diagnosis of MO was made on clinical, radiographic and laboratory findings, in particular the existence of at least two exostoses at the juxta-epiphysial regions of the long bones (Legeai-Mallet et al., 1997).

Sanger Sequencing

Genomic DNA was extracted from peripheral blood using the QiAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Primers were designed by Primer Premier 3.0 to amplify each exon and intron/exon junction of the EXT1 and EXT2 genes (primer sequences and PCR conditions are available upon request). The resulting PCR products were sequenced on the ABI 3730XL DNA Genetic Analyzer (Applied Biosystems, Foster City, CA), using the ABI BigDye Terminator v3.1 Cycle Sequencing Kit.

Whole-Exome Sequencing

Genomic DNA was fragmented randomly and then purified by means of the magnetic particle method. Sequences were captured by Agilent SureSelect version 4 (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s protocols. The DNA libraries, after enrichment and purification, were sequenced on the NextSeq500 sequencer according to the manufacturer’s instructions (Illumina, San Diego). The sequencing reads were aligned to GRCh37.p10 using Burrows-Wheeler Aligner software (version 0.59) (Li and Durbin, 2009). Local realignment and
base quality recalibration of the Burrows-Wheeler aligned reads were then performed using the GATK IndelRealigner and GATK BaseRecalibrator, respectively. SNVs and small indels were identified by the GATK UnifiedGenotyper. Variants were annotated using the Consensus Coding Sequences Database at the National Centre for Biotechnology Information.

Multiplex Ligation-Dependent Probe Amplification, Fluorescence in situ Hybridization and Whole Genome Sequencing
These methods have been described in detail elsewhere (Su et al., 2015; Wang et al., 2015).

Reference Sequences and Variant Nomenclature
NM_000127.2 and NM_207122.1 were used as EXT1 and EXT2 mRNA reference sequences, respectively. Variant nomenclature followed HGVS recommendations (den Dunnen et al., 2016). Variants were checked against the Human Gene Mutation Database (HGMD) as well as the EXT1 or EXT2 locus-specific mutation database to identify previously described lesions (as of 12 Sep 2020). For those that were newly described here, their nomenclature was verified via VarSome (Kopanos et al., 2019).

Pathogenicity Predictions
The PP3 rule established by VarSome (Kopanos et al., 2019) was adopted to predict the pathogenicity of EXT1 missense variants as previously described (Gueguen et al., 2020). The PP3 verdict was based upon the combined consideration of predictions from a dozen in silico programs including VarSome, SIFT, MutationAssessor, MutationTaster, PrimateAI, REVEL and SIFT. In silico splicing prediction was performed by means of Alamut Visual v.2.11 rev. 0.1 (Interactive Biosoftware, Rouen, France) and SpliceAI. Alamut includes five prediction algorithms, namely SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder. SpliceAI is a recently developed deep residual neural network for splicing prediction (Jaganathan et al., 2019).

Structural Modeling of EXT1
Structural modeling of human EXT1 was carried out using the Robetta server. Model minimization was carried out using Discovery Studio 3.5 (Accelrys, San Diego, California). The refined model was validated by the VERIFY-3D program in Discovery Studio 3.5. The model figure was prepared using PyMol (DeLano, 2002).

Preimplantation Genetic Testing (PGT)
The oocyte retrieval, embryo culture, and biopsy methods were used as previously described (Liu et al., 2020). The biopsied trophoderm cells transferred to phosphate buffer saline were subjected to whole-genome amplification (WGA) using the Multiple Displacement Amplification approach (REPLI-g Single Cell Kit, QIAGEN Inc.).

Three couples were offered counseling and information on different PGT platforms. SNP microarrays were used for Family 4-II-3 and Family 13-II-5. The peripheral blood DNA of parents and reference samples (abortion with EXT1 mutation or affected parent), together with the embryo samples from the WGA, were analyzed using HumanKaryomap-12 BeadChips (Illumina, San Diego, CA, United States) according to the manufacturer's instructions. The scanning results were analyzed using BlueFuse Multi V4.5 software provided by Illumina. The haplotypes in each pedigree were performed in the EXT1 regions as well as 2 Mb upstream and downstream of this gene. At the same time, the B allele and Log R Ratio data were obtained from the scanning results produced by Illumina Genome studio 2.0 software for aneuploidy screening. Next-generation sequencing (NGS) platforms were used for the two PGT cycle in Family 5-II-3. The EXT1 region was selected as the target region. A total of 31 high density and closely linked SNPs mapping within 2 Mb upstream of the gene and 33 linked SNPs mapping within 2 Mb downstream of the gene, were selected. Following mixing with corresponding PCR amplicons of the SNPs and mutations, the WGA products were used for the library construction of NGS. DNA purification, cDNA library construction and sequencing using the Illumina MiSeqDX were performed sequentially. Haplotypes were established by selection of several informative SNPs. The mutations in all samples were subjected to Sanger sequencing for verification. For PGT-A (PTG for aneuploidies), the VeriSeq PGS-MiSeq kit (Illumina) was used to prepare the NGS libraries. The MiSeq Reagent Kit v3-PGS (Illumina, San Diego, CA, United States) was used to perform dual-index 36-bp read sequencing according to the VeriSeq PGS recipe. MiSeq Reporter software (Illumina, San Diego, CA, United States) was used to make on-board secondary data analysis (Fiorentino et al., 2014). Detection and classification of aneuploidies was determined by copy number variation (CNV) values. The frozen-thawed embryos without EXT1 mutations were transferred as previously described (Liu et al., 2020).

RESULTS
Clinical Features of the Patients
The family trees of the 22 families are presented in Figure 1. Four families have been previously described [i.e., family
FIGURE 1 | Pedigrees of the 22 Chinese families with multiple osteochondromas. Filled squares or circles denote patients. Open symbols denote clinically unaffected family members. Circles with question marks denote members with questionable clinical features and no imaging tests. Arrows indicate probands. + identifies those subjects subjected to genetic analysis. In Families 1–18, all patients subjected to genetic analysis harbored the variant of interest whereas the clinically healthy subjects did not. In Families 19–22, no pathogenic variants were found in any of the individuals subjected to genetic analysis. Those individuals who were born healthy through the preimplantation genetic testing are denoted by # whereas those who directly received prenatal diagnosis as a fetus are denoted by *. Subjects analyzed by WES were indicated by squares.

11 in Su et al. (2015) and families 16–18 in Wang et al. (2015) whereas the remaining 18 families are reported for the first time. Detailed information pertaining to the clinical features exhibited was available for 36 patients, and is summarized in Table 1. Specifically, in the informative patients, osteochondroma/exostoses generally occurred in the long bones of the upper and lower limbs; chest bones (rib, sternum, scapulae, claviculae) [27.8% (10/36)] and hip (ilium,
pubis, ischium) [11.1% (4/36)] were the next most commonly affected sites whereas vertebral osteochondroma/exostoses were found only in a single patient (i.e., Family 15-III-1). About 25.0% (9/36) of patients had a deformity of the limbs and joints whilst only three patients had pain in one or more affected locations. A total of 12 patients (33.3%) underwent surgery to correct the deformity. Finally, malignant transformation to chondrosarcoma occurred in two patients (i.e., Family 10-II-1 and Family 14-II-1) whilst the absence of a uterus was revealed in one patient (i.e., Family 7-III-1). Some aspects of the clinical features are also shown in Figure 2.

### Table 1 | Clinical characteristics of the multiple osteochondromas patients in 22 families.

| Patient | Sex  | Agea (years) | Location of exostoses | Other clinical phenotypes | Surgical therapy | Pain  |
|---------|------|--------------|------------------------|---------------------------|-----------------|-------|
| Family 1-II-1 | M | 19 | Femur, tibia, fibula, ulna | Forearm deformity | No | No |
| Family 2-II-1 | M | 23 | Femur, tibia, fibula, ulna, radius | Shortened ulna, negatively curved arm | No | No |
| Family 3-III-9 | M | 17 | Femur, tibia, fibula, ulna, radius, clavicle | Deformity of wrist joint, dislocation of acromioclavicular joint | Yes | No |
| Family 4-II-2 | M | 28 | Femur, tibia, fibula, ulna, radius, ilium, pubis | Forearm deformity, dislocation of radioulnar joint | Yes | No |
| Family 5-II-3 | F | 25 | Femur, tibia, fibula | No | No | No |
| Family 6-II-2 | F | 24 | Femur, tibia, fibula, ulna | No | No | No |
| Family 7-III-1 | F | 17 | Scapula, femur | Absence of uterus | No | No |
| Family 8-III-1 | M | 14 | Femur, tibia, fibula, ulna | – | No | – |
| Family 9-III-2 | M | 10 | Femur, tibia, fibula, ulna, radius, humerus, scapula | No | No | No |
| Family 10-II-1 | M | 27 | Radius, femur | Chondrosarcoma | Yes | Yes |
| Family 11-II-2 | F | 40 | Femur, tibia, ulna, radius | No | No | No |
| Family 11-III-1 | F | 11 | Femur, tibia, fibula, humerus, ulna, radius, ilium, pubis, ischium, clavicle, scapula, ribs, phalanx | Forearm deformity, dislocation of elbow joint | Yes | No |
| Family 11-III-2 | F | 9 | Scapula, clavicle, rib | No | No | No |
| Family 12-II-1 | M | 26 | Femur, tibia, ulna, radius, rib | Knee joint dysfunction | No | No |
| Family 13-II-1 | F | 37 | Femur, tibia, fibula | No | No | No |
| Family 13-III-3 | M | 4 | Tibia, fibula, ulna, radius, humerus | Scoliosis | No | No |
| Family 13-III-4 | F | 11 | Femur, tibia, fibula | No | No | No |
| Family 13-III-5 | M | 8 | Femur, tibia, fibula, humerus, ulna, radius, ilium, sternum, scapula, ribs | Scoliosis, thoracolumbar kyphosis, Vertebral fusion, hemivertebra deformity | Yes | No |
| Family 14-II-1 | F | 23 | Femur, tibia, fibula, rib | Chondrosarcoma | Yes | Yes |
| Family 15-III-1 | M | 13 | Femur, tibia, fibula, humerus, ulna, radius, ilium, pubis, vertebra | Knee joint dysfunction | Yes | No |
| Family 16-I-2 | F | 70 | Femur | Hip osteoarthritis, necrosis of femoral head, and scoliosis | No | Yes |
| Family 16-II-3 | M | 48 | Humerus, tibia, ulna, and radius | No | No | No |
| Family 16-II-5 | M | 45 | Femur, fibula, and radius | Dislocation of radioulnar joint | No | No |
| Family 16-II-8 | F | 40 | Femur and humerus | No | No | No |
| Family 16-III-1 | M | 26 | Femur, tibia, fibula, humerus, ulna and radius | Forearm deformity and wrist joint dysfunction | No | No |
| Family 16-III-5 | M | 13 | Femur, tibia, fibula, ulna, and radius | No | No | No |
| Family 16-III-9 | F | 7 | Femur and rib | No | No | No |
| Family 16-III-11 | M | 14 | Femur, tibia, fibula, humerus, ulna, and radius | No | Yes | No |
| Family 16-III-12 | M | 12 | Femur, tibia, fibula, humerus, ulna, and radius | No | Yes | No |
| Family 17-1-I | M | 45 | Femur and tibia | No | Yes | No |
| Family 17-II-1 | M | 13 | Femur, tibia, fibula, and phalanx | No | No | No |
| Family 18-II-1 | M | 10 | Femur, ulna, radius, and scapula | No | Yes | No |
| Family 19-II-1 | M | 25 | Femur, tibia, fibula | No | No | No |
| Family 20-II-1 | M | 24 | Humerus, femur, tibia | No | No | No |
| Family 21-II-1 | M | 19 | Femur, fibula, radius, ulna | No | No | No |
| Family 22-II-1 | M | 22 | Femur, tibia, fibula | No | No | No |

*a Age at the time of diagnosis.*
FIGURE 2 | Special exostosis lesions and complications in some affected MO individuals. (A,B) Radiographs of Family 13 member III-5 as anteroposterior and lateral views, revealing the scoliosis, thoracolumbar kyphosis and vertebral fusion (arrow). (C) Right forearm of Family 11 member III-1, showing exostosis in the ulna and dislocation of the elbow joint (arrow). (D) Right forearm of Family 4 member II-2, showing exostosis in the ulna and bowed forearm conferring dislocation of radioulnar joint (arrow). (E) Radiograph of Family 7 member III-1, revealing the exostoses in the scapula (arrow). (F) Radiograph of Family 4 member II-2, showing the exostosis at the right side of the first rib (arrow). (G) Pelvic radiograph of Family 4 member II-2, displaying exostosis on the left side of the ilium (arrow). (H) Ultrasound images of Family 7 member III-1, showing the absence of a uterus (arrow).
| Family | Gene | Location | Nucleotide change* | Protein change* | Type of mutation | Newly described here | Allele frequency in GnomAD | Family history | Methods |
|--------|------|----------|------------------|-----------------|-----------------|---------------------|-------------------------|----------------|---------|
| 1      | EXT1 | Exon 1   | c.368_369delinsC  | p.Lys123Thrfs*13| Frame shift     | –                   | –                      | Negative        | Sanger sequencing |
| 2      | EXT1 | Exon 1   | c.917delA        | p.Lys306Serfs*53| Frame shift     | Yes                 | –                      | Negative        | WES               |
| 3      | EXT1 | Exon 2   | c.1019G > A      | p.Arg340His      | Missense        | 3.98e-6             | Positive               | WES             |
| 4      | EXT1 | Exon 2   | c.1019G > A      | p.Arg340His      | Missense        | 3.98e-6             | Positive               | WES             |
| 5      | EXT1 | Exon 2   | c.1049_1051delinsAATCTGATTCC | p.Ala350Glufs*12 | Frame shift     | Yes                 | –                      | Positive        | WES               |
| 6      | EXT1 | Exon 3   | c.1065C > G      | p.Cys365Trp      | Missense        | –                   | Positive               | WES             |
| 7      | EXT1 | Intron 4 | c.1284 + 1G > C  | –                | Splice site     | –                   | Positive               | WES             |
| 8      | EXT1 | Exon 9   | c.1808_1838delinsTCCAGTGGGATA | p.Tyr603Ilefs*5  | Frame shift     | Yes                 | –                      | Positive        | WES               |
| 9      | EXT1 | Exon 10  | c.1942C > T      | p.Gln648*        | Non-sense       | –                   | Positive               | Sanger sequencing |
| 10     | EXT1 | Exon 10  | c.2034T > G      | p.Tyr678*        | Non-sense       | –                   | Positive               | Sanger sequencing |
| 11     | EXT1 | Exons 2–8| g.118825104_119054767dupins | –                | Structural variant | –                  | Positive               | Sanger + MLPA + WGS  |
| 12     | EXT1 | Exon 3   | c.544C > T       | p.Arg182*        | Non-sense       | –                   | Positive               | Sanger sequencing |
| 13     | EXT2 | Exon 5   | c.831_832delAG   | p.Glu278Valfs*7  | Frame shift     | Yes                 | 3.98e-6                | Positive        | Sanger sequencing |
| 14     | EXT2 | Intron 7 | c.1173 + 2dupT   | –                | Splice site     | Yes                 | –                      | Negative        | WES               |
| 15     | EXT2 | Exon 8   | c.1188G > A      | p.Trp396*        | Non-sense       | –                   | Positive               | Sanger sequencing |
| 16     | EXT2 | Whole gene| g.4396139_44438043delins | –                | Structural variant | –                  | Positive               | Sanger + FISH + MLPA + WGS  |
| 17     | EXT2 | Whole gene| g.4396139_44438043delinsGAGAAAGCATTGCAAAAAATGATGA | –                | Structural variant | –                  | Positive               | Sanger + MLPA + WGS  |
| 18     | EXT2 | Exons 2–8| g.44128440_44198500delinsTCTTG | –                | Structural variant | –                  | Positive               | Sanger + MLPA + WGS  |
| 19     | Undetected |         |                  | –                | Structural variant | –                  | Positive               | WES + MLPA      |
| 20     | Undetected |         |                  | –                | Structural variant | –                  | Positive               | Sanger sequencing + MLPA |
| 21     | Undetected |         |                  | –                | Structural variant | –                  | Positive               | Sanger sequencing + MLPA |
| 22     | Undetected |         |                  | –                | Structural variant | –                  | Negative               | Sanger sequencing + MLPA |

*aHGVS recommended nomenclature (www.hgvs.org/mutnomen/) was used to describe sequence variations. For the c. nomenclature, the A of the ATG translation initiation codon of the EXT1 (NM_000127) or EXT2 (NM_207122) was counted as + 1. For the g. nomenclature, the nucleotide positions were in accordance with hg19.*
FIGURE 3 | In silico analyses with respect to three novel variants. (A) Prediction of the potential effect of EXT1 c.1284+1G>C on splicing by Alamut. (B) Prediction of the potential effect of EXT2 c.1173+2dupT on splicing by Alamut. (C) Structure model of EXT1. The N-terminal region (amino acid residues 29–461) is shown here in cartoon form. Helix, sheet and loop are colored in red, yellow and green, respectively. The side chains of Cys355 and Cys334 are shown as spheres colored in cyan.
Pathogenic EXT1 and EXT2 Variants Found in the Patients

The EXT1 and EXT2 variants detected in 18 of the 22 families (i.e., families 1–18) are summarized in Table 2 alongside the detection methods employed. Of the 16 unique variants, the three large duplication or deletion variants (namely, duplication of EXT1 exons 2–8, deletion of the entire EXT2 gene, and deletion of exons 2–8 of EXT2) have been previously described in Su et al. (2015) and Wang et al. (2015). Of the remaining 13 variants, 6 were already logged in HGMD and/or EXT1 and EXT2 locus-specific mutation databases whereas 7 were not (as of 12 September 2020). The Sanger sequencing chromatograms for the seven newly described variants (5 in EXT1 and 2 in EXT2) are shown in Supplementary Figure S1. All 16 variants were either absent or present at extremely low frequency (<0.00001) in the Genome Aggregation Database (gnomAD) (Table 2). Additionally, in families (excepting the mutation-negative Families 19–22) where additional members were available for genetic analysis, the respective variants were invariably found in patients but not in healthy subjects (Figure 1).

Of the 16 unique variants, 12 appear to be loss of function by virtue of their nature, irrespective of whether or not they had been previously described; these included all frameshift (n = 5) and non-sense (n = 4) variants and the gross duplication and deletion (n = 3) variants. Of the two splice site variants identified, EXT1 c.1284 + 1G > C was also highly likely to be of pathological significance due to its disruption of the canonical 2-bp GT splice donor site (Lin et al., 2019); the Alamut prediction concurred with this assumption (Figure 3A). The pathogenic relevance of the EXT2 c.1173 + 2dupT variant was however immediately apparent because it did not alter the canonical 2-bp GT donor splice site. Alamut was therefore employed to predict its impact on splicing. As shown in Figure 3B, all five in silico algorithms provided by the Alamut suite under default conditions predicted that the variant allele would exhibit significantly reduced splicing potential as compared to the wild-type allele. We further employed the recently developed SpliceAI (Jaganathan et al., 2019) to predict the impact of the two splice-site variants on splicing and, as previously described (Chen et al., 2020), we further employed the recently developed SpliceAI (Jaganathan et al., 2019) to predict the impact of the two splice-site variants on splicing and, as previously described (Chen et al., 2020), we focused our analysis exclusively on the Delta scores of donor loss as although other scores may provide clues as to the nature of the resulting aberrantly spliced transcripts of splice-altering variants. Both variants were predicted to have a high probability of altering splicing, the Delta scores of donor loss being 0.91 and 0.99 for EXT1 c.1284 + 1G > C and EXT2 c.1173 + 2dupT, respectively (Delta scores range from 0 to 1, with 1 indicating the highest probability of altering splicing). As for the two missense variants (both in EXT1), c.1019G > A (p.Arg340His) has been reported in > 30 MO patients according to the EXT1 locus-specific mutation database and was predicted by VarSome to be pathogenic (verdict based on 11 pathogenic predictions from BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL, M-CAP, MVP, MutationAssessor, MutationTaster, PrimateAI, REVEL and SIFT vs. 1 benign prediction from SIFT). The newly described EXT1 c.1065C > G (p.Cys355Trp) was predicted by VarSome to be “likely pathogenic” (verdict based on 10 pathogenic predictions from BayesDel_addAF, DEOGEN2, FATHMM-MKL, M-CAP, MVP, MutationAssessor, MutationTaster, PrimateAI, REVEL and SIFT vs. 2 benign predictions from DANN and EIGEN). Most importantly, two other missense variants that affected the p.Cys355 site, p.Cys355Arg and p.Cys355Tyr, have previously been identified in MO patients (Jennes et al., 2009; Ishimaru et al., 2016), adding significant weight to our contention that p.Cys355Trp is of pathological relevance. To provide further insight into this question, we performed structural modeling of EXT1. The N-terminal region of EXT1 belongs to the GT47 family, but protein structure information from this domain is so far lacking. We therefore used the latest TrRosetta method on Robetta server (Hiranuma et al., 2020; Yang et al., 2020), a deep learning-based method, to predict the structure of human EXT1. This model shows that the N-terminal part of EXT1 comprises two domains, which adopt a GT-B-like fold. The classical GT-B fold is composed of two distinct N-terminal and C-terminal Rossmann-like domains of six or seven parallel-sheet linked...
to α-helices, connected by a linker region and an interdomain cleft. This model predicted that the Cys355 is located in the center of the second lobe and can form a disulfide bond with Cys334 (Figure 3C). Therefore, Cys355 probably plays a critical role in stabilizing the protein; substitution of Cys by a larger hydrophobic residue Trp (and other residues) would abolish the disulfide bond, thereby impacting both the stability and enzymatic activity of EXT1.

In short, pathogenic variants were found in 82% (n = 18) of the 22 MO families, with EXT1 and EXT2 variants being detected in 50% (11/22) and 32% (7/22) of cases, respectively. Figure 4 illustrates these variants in terms of their locations within their respective gene/protein sequences.

Families 19–22 remained genetically unexplained after whole-exome sequencing (WES) or Sanger sequencing followed by MLPA (Table 2). Karyotyping was further performed on probands of families 19, 20, and 21, showing no chromosome abnormalities (Supplementary Figure S2). This served to rule out the presence of chromosome rearrangements in excess of 5–10 MB in the three cases. Finally, family 19-II-1 was analyzed by WES, the resulting variants of unknown significance are provided in Supplementary Table S1.

### Table 3 | Summary of PGT-M/PGT-A results from three families.

| Sample no. | PGT cycle | Biopsy time | Embryo | PGT-M result | PGT-A result | Outcome |
|------------|------------|-------------|--------|---------------|---------------|---------|
|            |            |             | Haptype| Sanger Sequencing|              |         |
| Family 4-II-3 | 1 Day 5 | Embryo-1 | Affected | Heterozygote | + 21 | Transfer |
| Day 5 | Embryo-2 | Normal | Normal | Normal | Euploid |
| Day 5 | Embryo-3 | Normal | Normal | Normal | Euploid |
| Day 5 | Embryo-4 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-5 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-6 | Normal | Normal | Euploid | Euploid |
| Day 5 | Embryo-7 | Affected | Heterozygote | Euploid | |
| Day 6 | Embryo-8 | Normal | Normal | Euploid | |
| Day 6 | Embryo-9 | Normal | Normal | Euploid | |
| Day 6 | Embryo-10 | Normal | Normal | Euploid | |
| Day 6 | Embryo-7 | Maternal | Affected | Haploidy | |
| Day 5 | Embryo-1 | Maternal | Heterozygote | −8, + 22 | |
| Day 5 | Embryo-2 | Affected | Heterozygote | −15 | |
| Day 5 | Embryo-3 | Normal | Normal | Euploid | Transfer |
| Day 5 | Embryo-4 | Affected | Heterozygote | + 8q14.3 | |
| Day 5 | Embryo-5 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-6 | Normal | Normal | Euploid | |
| Day 6 | Embryo-7 | Normal | Normal | Euploid | |
| Day 6 | Embryo-8 | Normal | Normal | Euploid | |
| Family 5-II-3 | 1 Day 5 | Embryo-1 | Normal | Normal | −22 | |
| Day 5 | Embryo-2 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-3 | Normal | Normal | Euploid | |
| Day 5 | Embryo-4 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-5 | Affected | Heterozygote | Euploid | |
| Day 6 | Embryo-6 | Normal | Normal | Euploid | |
| Day 6 | Embryo-7 | Normal | Normal | Euploid | |
| Day 6 | Embryo-8 | Normal | Normal | Euploid | |
| Day 6 | Embryo-9 | Normal | Normal | Euploid | |
| Family 13-II-5 | 1 Day 5 | Embryo-1 | Normal | Normal | Euploid | Transfer |
| Day 5 | Embryo-2 | Affected | Heterozygote | Euploid | |
| Day 6 | Embryo-3 | Affected | Heterozygote | Euploid | |
| Family 13-II-5 | 2 Day 5 | Embryo-1 | Affected | Heterozygote | −15 | |
| Day 5 | Embryo-2 | Affected | Heterozygote | + 22 | |
| Day 5 | Embryo-3 | Normal | Normal | Euploid | |
| Day 5 | Embryo-4 | Affected | Heterozygote | Euploid | |
| Day 5 | Embryo-5 | Affected | Heterozygote | Euploid | |
| Day 6 | Embryo-6 | Normal | Normal | Euploid | |
| Day 6 | Embryo-7 | Normal | Normal | Euploid | |
| Day 6 | Embryo-8 | Normal | Normal | Euploid | |
| Family 13-II-5 | 1 Day 5 | Embryo-1 | Normal | Normal | Euploid | |
| Day 5 | Embryo-2 | Affected | Heterozygote | Euploid | |
| Day 6 | Embryo-3 | Affected | Heterozygote | Euploid | |

### Table 4 | Summary of the results of prenatal diagnosis in five families.

| Sample no. | Number of prenatal diagnoses | Gestation, weeks | Fetus | Methods | Result | Outcome |
|------------|------------------------------|------------------|-------|---------|--------|---------|
| Family 6-II-2 | 1 | 17 + 6 W | Family 6-II-2 | Sanger sequencing | Normal | Born healthy |
| Family 7-II-2 | 1 | 17 + 5 W | Family 7-II-2 | Sanger sequencing | Normal | Born healthy |
| Family 10-II-2 | 1 | 17 + 4 W | Family 10-II-2 | Sanger sequencing | Heterozygote | Labor induction |
| Family 11-II-3 | 1 | 18 + 2 W | Family 11-II-3 | MLPA + chromosome microarray analysis | Normal | Born healthy |
| Family 12-II-2 | 1 | 17 + 3 W | Family 12-II-2 | Sanger sequencing | Heterozygote | Labor induction |
| Family 12-II-2 | 2 | 17 W | Family 12-II-2 | Sanger sequencing | Normal | Born healthy |
Preimplantation Genetic Testing and Prenatal Diagnosis in 8 MO Families

As MO is an autosomal dominant skeletal disorder, the risk of this disease appearing in the offspring of an affected individual is expected to be approximately 50%. It is therefore extremely important in such cases to be able to provide prenatal diagnosis or PGT with a view to preventing the reoccurrence of MO in the affected families. Of the 18 MO families in which a genetic cause could be unequivocally established, eight sought assistance with this issue (those who were born healthy through the PGT were marked with #, and those who directly received prenatal diagnosis as a fetus were marked with * in Figure 1).

Specifically, three couples conceived through in vitro fertilization after PGT, a technique whereby a 5-day-old embryo is tested in a laboratory to determine if it carries a particular disease-causing variant. The three couples (Family 4-II-3, Family 5-II-3, and Family 13-II-5) underwent a total of four PGT cycles. Trophoderm biopsy and PGT-M/PGT-A (PGT for Monogenic defects/PGT for Aneuploidies) were performed on the 27 blastocysts. Twelve (44.4%) of the 27 embryos were found not to harbor any EXT mutations by PGT-M whereas 13 of the 27 embryos were found to be euploid by means of PGT-A (Table 3). Three embryos (Embryo-2 of Family 4-II-3, Embryo-6 of Family 5-II-3 and Embryo-1 of Family 13-II-5) found to be both mutative-negative and euploid were used for transfer, all resulting in healthy live births at full term. Moreover, two of the three PGT babies were subjected to prenatal diagnosis, both showing no EXT1/EXT2 mutations.

The other five couples (Family 6-II-2, Family 7-II-2, Family 10-II-2, Family 11-II-3, and Family 12-II-2) elected to undergo prenatal diagnosis on the fetus after the mothers had conceived naturally. Genomic DNA, prepared from amniotic fluid cells taken by ultrasound-guided amniocentesis at about 17 weeks of gestation, was used to investigate whether or not the fetus carried the pathogenic variant. The results and outcomes of prenatal diagnosis in the 5 families were summarized in Table 4. Pathogenic mutations were detected in the fetuses in families 10 and 12, and in both cases the pregnant women elected to terminate the pregnancies. Fortunately, no mutations were detected during the second pregnancy of Family 12-II-2.

In summary, seven babies from the eight MO families that underwent either PGT or prenatal diagnosis were born healthy and no abnormalities were observed in follow-up studies.

DISCUSSION

In the present study, we describe the analysis of the pathogenetic basis of multiple osteochondromas (MO) in 22 Chinese families. Our findings concur with those published previously in terms of the overall variant detection rate, a preponderance of EXT1 variants as compared to EXT2 variants, and the predominance of truncating variants (Santos et al., 2018; Fusco et al., 2019). Nonetheless, several points are worth noting. First, in addition to the previously described large EXT1 duplication (Su et al., 2015) and two large EXT2 deletions (Wang et al., 2015), seven novel variants were identified, thereby expanding the mutational spectrum of the EXT1 and EXT2 genes in MO. Notably, we identified a novel missense variant, p.Cys355Trp, in one family. The previous report of two other missense variants affecting the same amino acid, together with our newly modeled EXT1 structure, provide firm support for the pathogenicity of p.Cys355Trp. Second, a higher frequency (22.2%) of large deletion or duplication variants was detected in our cohort than in other studies (e.g., 4–9% in White et al., 2004; Signori et al., 2007; Jennes et al., 2008; Pedrini et al., 2011; Delgado et al., 2014), although it should be born in mind that our cohort was relatively small. Third, the absence of a uterus was discovered in a female MO patient in Family 7-III-1. To the best of our knowledge, this is the first time that such a phenotype has been reported in an MO patient. Whether this was due directly to the EXT1 c.1284 + 1G > C variant identified or to a defect in another unrelated gene(s) is unclear.

Four families (Families 19, 20, 21, and 22) were variant-negative after WES or Sanger sequencing followed by MLPA (Table 2). Families 19, 20, and 21 were additionally analyzed by karyotyping and MLPA (Supplementary Figure S2). However, MLPA and karyotyping could not readily detect cryptic balanced rearrangements such as inversions potentially affecting the EXT1 and/or EXT2 genes; and WES and Sanger sequencing did not target the vast intronic and regulatory regions of the EXT1 and EXT2 genes. Moreover, mosaic variants below the mutation detection threshold may be responsible for the mutation-negative probands in Families 20–22 (as well as for some mutation-negative parents in genetically explained families, i.e., parents in Families 1, 2, and 14). Alternatively, these families may be due to variants in the as yet uncloned EXT3 gene (Le Merrer et al., 1994). Finally, it should be noted that we have tried but failed to perform whole genome sequencing on the probands of Families 19–22 and WES on the probands of Families 20–22 owing to the poor quality and/or insufficient amount of DNA.

Prenatal diagnosis and PGT are the only ways to prevent the reoccurrence of MO in affected families. In this regard, prenatal diagnosis of MO has been previously described in the literature but in each report, at most two cases were studied (Zhao et al., 2009; Zhu et al., 2011; Tang et al., 2013; Bai et al., 2020). Herein, we described the processes and outcomes of prenatal diagnosis in seven families, including five families who received prenatal diagnosis directly, and two families who received prenatal diagnosis to validate PGT results. Our study is thus the largest to date in terms of reported MO patients who received prenatal diagnosis. Moreover, to the best of our knowledge, this is the first time that PGT has been successfully implemented in MO families.

In summary, we identified 16 unique pathogenic EXT1 and EXT2 variants (including seven novel ones) in 18 (82%) of 22 Chinese MO families, which has expanded further the mutational spectrum of MO-causing variants in the two genes. The identification of causative variants allowed us to provide genetic counseling to 8 MO patients in terms either of PGT or prenatal diagnosis, thereby preventing the reoccurrence of the disease in the respective affected families. This is the first report of the successful implementation of PGT in affected MO
families and also the largest study in terms of reported subjects undergoing prenatal diagnosis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA665773.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Sun Yat-sen University. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

YW and YL designed the study. YW, LZ, and YJ performed the genetic analysis and bioinformatics evaluations. CX, LD, and YW and YL designed the study. YW, LZ, and YJ performed the clinical and imaging evaluations. YX conducted the clinical and imaging evaluations. YY assisted with the bioinformatics analysis. CF and DC contributed to data interpretation. All authors contributed to manuscript revision and approved the final manuscript.

REFERENCES

Ahn, J., Ludecke, H. J., Lindow, S., Horton, W. A., Lee, B., Wagner, M. J., et al. (1995). Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat. Genet. 11, 137–143. doi: 10.1038/ng1095-137

Bai, Y., Jiao, Z., Liu, N., Hu, S., Zhao, K., and Kong, X. (2020). [Genetic analysis of five pedigrees affected with multiple osteochondromas]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 37, 717–720. doi: 10.3760/cma.j.issn.1003-9406.2020.07.004

Bovee, J. V. (2008). Multiple osteochondromas. Orphanet J. Rare Dis. 3:3. doi: 10.1186/1750-1172-3-3

Busse, M., Feta, A., Presto, J., Wilen, M., Gronning, M., Kjellén, L., et al. (2007). Contribution of EXT1, EXT2, and EXT3 to heparan sulfate chain elongation. J. Biol. Chem. 282, 32802–32810. doi: 10.1074/jbc.M703560200

Chen, J. M., Lin, J. H., Masson, E., Liao, Z., Férec, C., Cooper, D. N., et al. (2020). The experimentally obtained functional impact assessments of 5’ splice site GT>GC variants differ markedly from those predicted. Curr. Genomics 21, 56–66. doi: 10.2174/1389202921666200210141701

Clines, G. A., Ashley, J. A., Shah, S., and Lovett, M. (1997). The structure of the human multiple exostoses 2 gene and characterization of homologs in mouse and Caenorhabditis elegans. Genome Res. 7, 359–367. doi: 10.1101/gr.7.4.359

D’Arienzo, A., Andreani, L., Sacchetti, F., Colangeli, S., and Capanna, R. (2019). Hereditary multiple exostoses: current insights. Orthop. Res. Rev. 11, 199–211. doi: 10.2147/ORR.S183979

DeLano, W. L. (2002). The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific.

Delgado, M. A., Martinez-Domenech, G., Sarroion, P., Urreizti, R., Zecchini, L., Robledo, H. H., et al. (2014). A broad spectrum of genomic changes in Latinamerican patients with EXT1/EXT2-CDG. Sci. Rep. 4:6407. doi: 10.1038/srep06407

den Dunnen, J. T., Dalglish, R., Maglott, D. R., Hart, R. K., Greenblatt, M. S., McGowan-Jordan, J., et al. (2016). HGVS recommendations for the description of sequence variants: 2016 update. Hum. Mutat. 37, 564–569. doi: 10.1002/humu.22981

Fioentino, F., Biricik, A., Bono, S., Spizzichino, L., Cotroneo, E., Cottone, G., et al. (2014). Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertil. Steril. 101, 1375–1382. doi: 10.1016/j.fertnstert.2014.01.051

Fusco, C., Nardella, G., Fischetto, R., Copetti, M., Petracca, A., Annunziata, F., et al. (2019). Mutational spectrum and clinical signatures in 114 families with hereditary multiple osteochondromas: insights into molecular properties of selected exostin variants. Hum. Mol. Genet. 28, 2133–2142. doi: 10.1093/hmg/ddz046

Gueguen, P., Dupuis, A., Py, J. Y., Despres, A., Masson, E., Marechal, C. L., et al. (2020). Pathogenic and likely pathogenic variants in at least five genes account for approximately 3% of mild isolated nonsyndromic thrombocytopaenia. Transfusion 60, 2419–2431. doi: 10.1111/trf.15992

Hiranuma, N., Park, H., Anishchanka, I., Baek, M., and Baker, D. (2020). Improved protein structure refinement guided by deep learning based accuracy estimation. bioRxiv [Preprint] doi: 10.1101/2020.07.17.209643

Ishimaru, D., Gotoh, M., Takayama, S., Kosaki, R., Matsumoto, Y., Narimatsu, H., et al. (2016). Large-scale mutational analysis in the EXT1 and EXT2 genes for Japanese patients with multiple osteochondromas. BMC Genet. 17:52. doi: 10.1186/s12863-016-0359-4

Jaganathan, K., Kyriazopoulos, P. S., McRae, J. F., Darbandi, S. F., Knowles, D., Li, Y., et al. (2019). Predicting splicing from primary sequence with deep learning. Cell 176, 535–548. doi: 10.1016/j.cell.2018.12.015

Jennes, I., Entius, M. M., Van Hul, E., Parra, A., Sangiorgi, L., and Wuyts, W. (2008). Mutation screening of EXT1 and EXT2 by denaturing high-performance liquid chromatography, direct sequencing analysis, fluorescence in situ hybridization, and a new multiplex ligation-dependent probe amplification probe set in patients with multiple osteochondromas. J. Mol. Diagn. 10, 85–92. doi: 10.2353/jmoldx.2008.070086

Jennes, I., Pedrini, E., Zuntini, M., Mordenti, M., Balkassmi, S., Asteegiano, C. G., et al. (2009). Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum. Mutat. 30, 1620–1627. doi: 10.1002/humu.21123

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.607838/full#supplementary-material
Kopanos, C., Tsiofkas, V., Kouris, A., Chapple, C. E., Albarca, A. M., Meyer, R., et al. (2019). VarSome: the human genomic variant search engine. Bioinformatics 35, 1978–1980. doi:10.1093/bioinformatics/bty897

Le Merrr, M., Legeai-Mallet, L., Jeannin, P. M., Horsthemke, B., Schinzel, A., Plauchu, H., et al. (1994). A gene for hereditary multiple exostoses maps to chromosome 19p. Hum. Mol. Genet. 3, 717–722. doi:10.1093/hmg/3.5.717

Legeai-Mallet, L., Munnich, A., Maroteaux, P., and Le Merrr, M. (1997). Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clin. Genet. 52, 12–16. doi:10.1111/j.1399-0004.1997.tb02508.x

Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760. doi:10.1093/bioinformatics/btp324

Li, Y., Wang, J., Tang, J., Wang, Z., Han, B., Li, N., et al. (2018). Heterogeneous spectrum of EXT gene mutations in Chinese patients with hereditary multiple osteochondromas. Medicine (Baltimore) 97:e12855. doi:10.1097/MD.0000000000012855

Lin, J. H., Tang, X. Y., Boulling, A., Zou, W. B., Masson, E., Fichou, Y., et al. (2019). First estimate of the scale of canonical 5’ splice site GT>GC variants capable of generating wild-type transcripts. Hum. Mutat. 40, 1856–1873. doi:10.1002/humu.23821

Lind, T., Tufaro, F., McCormick, C., Lindahl, U., and Lidholt, K. (1998). The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J. Biol. Chem. 273, 26265–26268. doi:10.1074/jbc.273.a126265

Liu, X. Y., Fan, Q., Wang, J., Li, R., Xu, Y., Guo, J., et al. (2020). Higher chromosomal abnormality rate in blastocysts from young patients with idiopathic recurrent pregnancy loss. Fertil. Steril. 113, 853–864. doi:10.1016/j.fertnstert.2019.11.016

Ludecke, H. J., Ahn, J., Lin, X., Hill, A., Wagner, M. J., Schomberg, L., et al. (1997). Genomic organization and promoter structure of the human EXT1 gene. Genomics 40, 351–354. doi:10.1006/geno.1996.4577

Matsubara, H., Tsuichiya, H., Sakurakichi, K., Yamashiro, T., Watanabe, K., and Tomita, K. (2006). Correction and lengthening for deformities of the forearm in multiple cartilaginous exostoses. J. Orthop. Sci. 11, 459–466. doi:10.1007/s00776-006-1047-4

McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L. E., Dyer, A. P., et al. (1998). The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat. Genet. 19, 158–161. doi:10.1038/514

Pedrini, E., De Luca, A., Valente, E. M., Maini, V., Capponcelli, S., Mordenti, M., et al. (2005). Novel EXT1 and EXT2 mutations identified by DHPLC in Italian patients with multiple osteochondromas. Hum. Mutat. 26, 280. doi:10.1002/humu.9339

Pedrini, E., Jennes, I., Tremosini, M., Milanesi, A., Mordenti, M., Parra, A., et al. (2011). Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of “protective” and “risk” factors. J. Bone Joint Surg. Am. 93, 2294–2302. doi:10.2106/JBJS.L.00949

Peterson, H. A. (1989). Multiple hereditary osteochondromata. Clin. Orthop. Relat. Res. 239, 222–230.

Porter, D. E., Lonie, L., Fraser, M., Dobson-Stone, C., Porter, J. R., and Simpson, A. H. (2004). Severity of disease and risk of malignant change in hereditary multiple exostoses. a genotype-phenotype study. J. Bone Joint Surg. Br. 86, 1041–1046. doi:10.1302/0301-620x.86b14.14815

Santos, S., Rizzo, I., Takata, R. I., Speck-Martins, C. E., Brum, J. M., and Sollaci, C. (2018). Analysis of mutations in EXT1 and EXT2 in Brazilian patients with multiple osteochondromas. Mol. Genet. Genomic Med. 6, 382–392. doi:10.1002/mgg3.3382

Schmale, G. A., Conrad, E. R., and Raskind, W. H. (1994). The natural history of hereditary multiple exostoses. J. Bone Joint Surg. Am. 76, 986–992. doi:10.2106/0004623-199407000-00005

Signori, E., Massi, E., Matera, M. G., Poscente, M., Gravina, C., Falcone, G., et al. (2007). A combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patients. Genes Chromosomes Cancer 46, 470–477. doi:10.1002/gcc.20429

Stenson, P. D., Mort, M., Ball, E. V., Chapman, M., Evans, K., Azevedo, L., et al. (2020). The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum. Genet. 139, 1197–1207. doi:10.1007/s00439-020-02199-3

Stickens, D., Clines, G., Burbbee, D., Ramos, P., Thomas, S., Hogue, D., et al. (1996). The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat. Genet. 14, 25–32. doi:10.1038/ng0996-25

Su, P., Wang, Y., Cooper, D. N., Zhu, W., Huang, D., Pérez, C., et al. (2015). Disclosing the hidden structure and underlying mutational mechanism of a novel type of duplication CNV responsible for hereditary multiple osteochondromas. Hum. Mutat. 36, 758–763. doi:10.1002/humu.22815

Tang, Y., Zheng, D. Z., Guo, X. Y., Liao, J., and Lan, F. H. (2013). [Molecular diagnosis and prenatal diagnosis in a hereditary multiple osteochondromas family]. Beijing Da Xue Xue Bao Yi Xue Ban 45, 906–909.

Wang, Y., Su, P., Hu, B., Zhu, W., Li, Q., Yuan, P., et al. (2015). Characterization of 26 deletion CNVs reveals the frequent occurrence of micro-mutations within the breakpoint-flanking regions and frequent repair of double-strand breaks by templated insertions derived from remote genomic regions. Hum. Genet. 134, 589–603. doi:10.1007/s00439-015-1539-4

White, S. I., Vink, G. R., Kriek, M., Wuyts, W., Schouten, J., Bakker, B., et al. (2004). Two-color multiplex ligation-dependent probe amplification: Detecting genomic rearrangements in hereditary multiple exostoses. Hum. Mutat. 24, 86–92. doi:10.1002/humu.20054

Wicklund, C. L., Pauli, R. M., Johnston, D., and Hecht, J. T. (1995). Natural history study of hereditary multiple exostoses. Am. J. Med. Genet. 55, 43–46. doi:10.1002/ajmg.1320550113

Yang, J., Anishchenko, I., Park, H., Peng, Z., Ovchinnikov, S., and Baker, D. (2020). Improved protein structure prediction using predicted interresidue orientations. Proc Natl. Acad. Sci. U.S.A. 117, 1496–1503. doi:10.1073/pnas.1914677117

Zhao, W. Q., Song, S. J., Wei, Q., and Qiao, J. (2009). [A new EXT2 mutation in a Chinese family with hereditary multiple exostoses]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26, 241–244. doi:10.3760/cma.j.issn.1000-9406.2009.03.001

Zhu, H. Y., Hu, Y. L., Yang, Y., Wu, X., Zhu, R. F., Zhu, X. Y., et al. (2011). Mutation analysis and prenatal diagnosis of EXT1 gene mutations in Chinese patients with multiple osteochondromas. Chin. Med. J. (Engl) 124, 3054–3057.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Zhong, Xu, Ding, Ji, Schutz, Férez, Cooper, Xu, Chen and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.